šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Gilead Sciences, Inc. (GILD)
NASDAQ: GILD Ā· Real-Time Price Ā· USD
166.43
-0.10 (-0.06%)
At close: Nov 20, 2026, 4:00 PM EST
167.38
+0.95 (0.57%)
After-hours: Nov 20, 2026, 7:59 PM EST

Gilead Sciences Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Delivered strong 2025 results with 6% HIV and liver growth, robust HIV prevention momentum, and four major launches planned for 2026. Guidance calls for 4%-5% base business growth, 6% HIV growth, and $800M Sunlenca revenue, with continued shareholder returns and a strong pipeline.

  • The discussion highlighted advances in long-acting HIV therapies, prioritization of new integrase inhibitors, and expansion into inflammation and cell therapy. Next-generation CAR-Ts and in vivo approaches are being developed, with key data readouts expected in the coming year.

  • Long-acting HIV prevention injectables are driving rapid market growth, with strong early adoption and payer coverage. The pipeline is robust in both HIV and oncology, supported by disciplined business development and operational efficiency, positioning for sustained top-line and EPS growth.

  • Base revenues are growing strongly, driven by diversification, disciplined capital allocation, and new launches. Yeztugo's HIV prevention launch is exceeding expectations, with broad access and robust demand, while the pipeline includes long-acting injectables and advanced cell therapies. Manufacturing scale and a focus on China and late-stage assets support future growth.

  • Constructive policy engagement and a strong US focus underpin robust growth in HIV, liver, and oncology franchises. Yeztugo's rapid launch and access, pipeline advancements, and selective business development support long-term expansion.

  • Strong Q3 results driven by HIV and liver portfolios, with Biktarvy, Descovy, and Livdelzi leading growth. Yeztugo launch exceeded expectations, achieving rapid payer coverage. Full-year guidance raised for HIV and total product sales, while cell therapy faces ongoing headwinds.

  • Cell therapy access has expanded to community settings, with improved manufacturing and strong commercial performance. Anito-cel is on track for a 2026 launch in multiple myeloma, and new in vivo CAR-T technology promises broader, lower-cost access. FDA regulatory changes and robust pipeline developments support future growth.

  • Portfolio diversification and commercial execution are driving growth, with robust HIV and oncology pipelines and a strong focus on expanding PrEP access. Policy engagement and state-level programs support patient access, while upcoming launches and innovative dosing regimens position the business for long-term success.

  • Strong Q2 results and robust HIV prevention growth were driven by Sunlenca's successful launch and high market awareness. The pipeline is advancing with major launches in HIV and oncology, while business development and R&D investments are set to sustain long-term growth.

  • A clear focus on virology, oncology, and inflammation drives a diverse pipeline, with key HIV and oncology trials progressing and new CAR-T and immunology assets in development. Notable updates include ARTISTRY and PURPOSE studies, Trodelvy expansion, and anito-cel's path to market.

  • Second quarter saw strong growth in HIV, oncology, and liver disease, highlighted by the successful launch of YEZTUGO and robust sales of BIKTARVY and DESCOVY. Full-year guidance was raised for revenue and EPS, with continued momentum expected in key therapeutic areas.

  • Key growth areas include HIV, oncology, and inflammation, with imminent launch of lenacapavir for PrEP and robust late-stage pipelines. Trodelvy is poised to become a new standard in breast cancer, while cell therapy and global expansion drive future opportunities.

  • Key pipeline advances include imminent lenacapavir launch for HIV prevention, strong TRODELVY data in first-line triple-negative breast cancer, and promising anito-cel CAR-T results. Early-stage immunology assets and next-generation cell therapies are also progressing.

  • Key pipeline advances include imminent lenacapavir launch for HIV prevention, strong TRODELVY data in first-line triple-negative breast cancer, and promising Anito-cel CAR-T results for myeloma. Early-stage immunology and rheumatology programs are progressing, with multiple launches anticipated.

  • The discussion highlighted a robust pipeline with imminent launches in HIV and oncology, a strong focus on diversification, and strategic use of AI for efficiency. The company is well-positioned against industry headwinds due to its U.S.-centric IP, disciplined capital allocation, and proactive approach to healthcare reform.

  • Anito-cel demonstrates high response rates and a strong safety profile, supporting its potential as an outpatient therapy for myeloma. Manufacturing advances and a growing global footprint position the product for a 2026 launch, while next-gen CAR-T constructs and solid tumor programs expand the pipeline.

  • Disciplined execution and scenario planning underpin growth despite regulatory uncertainty. Lenacapavir's launch is set to transform HIV prevention, with flexible access models and a strong switch strategy. Biktarvy maintains robust growth and market leadership.

  • AGM 2025

    The meeting covered strong 2024 financial results, robust pipeline progress, and the election of all director nominees. Shareholder proposals on compensation, governance, human rights, and DEI were discussed but not approved. Strategic focus remains on innovation, disciplined capital use, and global access to medicines.

  • Base business grew 4% year-over-year, led by HIV and liver disease, while total product sales declined 1% due to lower VEKLURY sales. Strong operating margin and EPS were reported, with multiple launches ahead, including lenacapavir for PrEP and Trodelvy in new indications.

  • Anito-cel BCMA CAR-T demonstrates strong efficacy and safety, with a 2026 launch planned and a focus on rapid manufacturing and global expansion. Outpatient delivery and modular accreditation are key to broader access, while next-gen bispecific CAR-Ts and autoimmune indications are advancing.

  • Strong 2024 growth is expected to continue, with 2025 temporarily impacted by policy and FX headwinds. Lenacapavir PrEP's mid-2024 launch aims to transform HIV prevention, while targeted market expansion and new product launches in HIV, liver, and oncology support a robust outlook.

  • Management outlined a strategy focused on sustained HIV leadership, rapid expansion in long-acting treatments, and diversification into oncology and inflammation. Financial discipline, robust cash flow, and a strong pipeline support growth and shareholder returns.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018